Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11).
»
Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11).
We conduct exploratory biomarker study of a phase II clinical trial of eribulin plus gemcitabine (EG) versus paclitaxel plus gemcitabine (PG) in metastatic breast cancer HER2-negative (BC) patients.We conducted targeted deep sequencing with adjustable cancer gene panel and RNA expression assay. Tumor mutation load (TMB) and mutation signature is determined based on a genetic change in a targeted area. Gene variation analysis performed by PanCancer set Immune Pathway Profiling and PanCancer Panel. Statistical analysis was performed to identify the relationship between genetic changes and clinical outcomes.Of 119 patients, 40 had a biomarker data available.
Among the 40 patients, 4 post-treatment network support them. In targeted sequencing in, FAT3 (48%) is the most frequently mutated gene, followed by PKHD1, TP53, GATA3, PARP4, and PIK3CA. In terms of gene expression, low expression of epithelial-mesenchymal transition (EMT) pathway genes associated with prolonged progression-free survival (PFS) in the group EG, while high expression of EMT pathway is associated with a good prognosis in the PG group. TMB median was 6.5 (range 2.44 to 46.34) and no association between TMB and the patient’s prognosis.
Signature mutation analysis showed that the signature of 3, 20, and 26 which are often observed in our group. Survival analysis Furthermore, according to the signature mutations shows that mutations signature 3, as signature-related deficiencies homologous recombinant, it is strongly associated with disease progression (hazard ratio (log2 scale) 8:21, the 95% confidence interval 2.93 to 13.48 , p = 0.002).
Kaplan-Meier plot also shows that the BCs with signature 3 has a shorter PFS compared with those who did not sign this (median PFS (months) for signing 3 (low vs. high): 17.2 vs. 8.1, p = 0, 0026) .Mutation signature 3, found in about 30% of MBCS regardless of hormone receptor status, was associated with shorter PFS for patients with cytotoxic chemotherapy.
Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11).
Modifications PARP4, XRCC3, and RAD51 Gene Polymorphism on the relationship between Bisphenol A Exposure and liver abnormalities.
repair genes may play an important role in the relationship between environmental exposures and health outcomes. However, no evidence was available about the effect of genetic polymorphisms on the improvement of the relationship between bisphenol A (BPA) exposure and liver abnormalities.
Therefore, we evaluated the effect of nine polymorphism genotypes in three genes repair, poly (ADP-ribose) member polymerase family of 4 (PARP4), X-ray repair cross-complementary 3 (XRCC3), and RAD51 recombinase (RAD51), in relation between exposure to BPA and heart abnormalities using repeated measures of data for the elderly population.
A significant association between BPA levels and liver abnormalities are found only in elders with PARP4 haplotype GCG, XRCC3 GAG haplotype, or RAD51 TAA haplotype (odds ratio (OR) = 2.16 and p = 0.0014 for PARP4; OR = 1.57 and p = 0.0249 for XRCC3; OR = 1.43 and p = 0.0422 for RAD51). Especially, PARP4 and XRCC3 showed significant interaction with BPA exposure in relation to liver abnormalities (p <0.05 for both genes). These results indicate that PARP4, XRCC3, and RAD51 gene polymorphism has the effect of modifications on the relationship between exposure to BPA and heart abnormalities.
Colorectal neuroendocrine tumors (nets) are rare neoplasms and study of colorectal nets is relatively small compared with other tumors. To better understand the pathogenesis of this tumor, we performed whole genome sequencing and follow-up verification using Sanger sequencing of colorectal and paired Nets para-tumor tissue.
Description: A polyclonal antibody for detection of PARP-2 from Human, Mouse. This PARP-2 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human PARP-2 at AA rangle: 120-200
Description: A polyclonal antibody for detection of PARP-2 from Human, Mouse. This PARP-2 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human PARP-2 at AA rangle: 120-200
Description: A polyclonal antibody for detection of PARP-2 from Human, Mouse. This PARP-2 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human PARP-2 at AA rangle: 120-200
Description: A polyclonal antibody for detection of PARP-3 from Human. This PARP-3 antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the N-terminal region of human PARP-3 at AA rangle: 10-90
Description: A polyclonal antibody for detection of PARP-3 from Human. This PARP-3 antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the N-terminal region of human PARP-3 at AA rangle: 10-90
Description: A polyclonal antibody for detection of PARP-3 from Human. This PARP-3 antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the N-terminal region of human PARP-3 at AA rangle: 10-90
Description: A polyclonal antibody for detection of PARP-1 from Human, Mouse, Rat. This PARP-1 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human PARP-1
Description: A polyclonal antibody for detection of PARP-1 from Human, Mouse, Rat. This PARP-1 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human PARP-1
Description: A polyclonal antibody for detection of PARP-1 from Human, Mouse, Rat. This PARP-1 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human PARP-1
Description: This gene encodes a chromatin-associated enzyme, poly(ADP-ribosyl)transferase, which modifies various nuclear proteins by poly(ADP-ribosyl)ation. The modification is dependent on DNA and is involved in the regulation of various important cellular processes such as differentiation, proliferation, and tumor transformation and also in the regulation of the molecular events involved in the recovery of cell from DNA damage. In addition, this enzyme may be the site of mutation in Fanconi anemia, and may participate in the pathophysiology of type I diabetes.
Description: This gene encodes a chromatin-associated enzyme, poly(ADP-ribosyl)transferase, which modifies various nuclear proteins by poly(ADP-ribosyl)ation. The modification is dependent on DNA and is involved in the regulation of various important cellular processes such as differentiation, proliferation, and tumor transformation and also in the regulation of the molecular events involved in the recovery of cell from DNA damage. In addition, this enzyme may be the site of mutation in Fanconi anemia, and may participate in the pathophysiology of type I diabetes.
Description: This gene encodes a chromatin-associated enzyme, poly(ADP-ribosyl)transferase, which modifies various nuclear proteins by poly(ADP-ribosyl)ation. The modification is dependent on DNA and is involved in the regulation of various important cellular processes such as differentiation, proliferation, and tumor transformation and also in the regulation of the molecular events involved in the recovery of cell from DNA damage. In addition, this enzyme may be the site of mutation in Fanconi anemia, and may participate in the pathophysiology of type I diabetes.
Description: PARP1 (poly(ADP-ribose) polymerase 1) encodes a chromatin-associated enzyme, poly(ADP-ribosyl)transferase, which modifies various nuclear proteins by poly(ADP-ribosyl)ation. The modification is dependent on DNA and is involved in the regulation of various important cellular processes such as differentiation, proliferation, and tumor transformation and also in the regulation of the molecular events involved in the recovery of cell from DNA damage. In addition, this enzyme may be the site of mutation in Fanconi anemia, and may participate in the pathophysiology of type I diabetes.
Description: PARP1 (poly(ADP-ribose) polymerase 1) encodes a chromatin-associated enzyme, poly(ADP-ribosyl)transferase, which modifies various nuclear proteins by poly(ADP-ribosyl)ation. The modification is dependent on DNA and is involved in the regulation of various important cellular processes such as differentiation, proliferation, and tumor transformation and also in the regulation of the molecular events involved in the recovery of cell from DNA damage. In addition, this enzyme may be the site of mutation in Fanconi anemia, and may participate in the pathophysiology of type I diabetes.
Description: PARP1 (poly(ADP-ribose) polymerase 1) encodes a chromatin-associated enzyme, poly(ADP-ribosyl)transferase, which modifies various nuclear proteins by poly(ADP-ribosyl)ation. The modification is dependent on DNA and is involved in the regulation of various important cellular processes such as differentiation, proliferation, and tumor transformation and also in the regulation of the molecular events involved in the recovery of cell from DNA damage. In addition, this enzyme may be the site of mutation in Fanconi anemia, and may participate in the pathophysiology of type I diabetes.
Description: PARP2 encodes poly(ADP-ribosyl)transferase-like 2 protein, which contains a catalytic domain and is capable of catalyzing a poly(ADP-ribosyl)ation reaction. Poly [ADP-ribose] polymerase 2 has a catalytic domain which is homologous to that of poly (ADP-ribosyl) transferase, but lacks an N-terminal DNA binding domain which activates the C-terminal catalytic domain of poly (ADP-ribosyl) transferase. The basic residues within the N-terminal region of this protein may bear potential DNA-binding properties, and may be involved in the nuclear and/or nucleolar targeting of the protein. Two alternatively spliced transcript variants encoding distinct isoforms have been found.
Description: PARP2 encodes poly(ADP-ribosyl)transferase-like 2 protein, which contains a catalytic domain and is capable of catalyzing a poly(ADP-ribosyl)ation reaction. Poly [ADP-ribose] polymerase 2 has a catalytic domain which is homologous to that of poly (ADP-ribosyl) transferase, but lacks an N-terminal DNA binding domain which activates the C-terminal catalytic domain of poly (ADP-ribosyl) transferase. The basic residues within the N-terminal region of this protein may bear potential DNA-binding properties, and may be involved in the nuclear and/or nucleolar targeting of the protein. Two alternatively spliced transcript variants encoding distinct isoforms have been found.
Description: PARP2 encodes poly(ADP-ribosyl)transferase-like 2 protein, which contains a catalytic domain and is capable of catalyzing a poly(ADP-ribosyl)ation reaction. Poly [ADP-ribose] polymerase 2 has a catalytic domain which is homologous to that of poly (ADP-ribosyl) transferase, but lacks an N-terminal DNA binding domain which activates the C-terminal catalytic domain of poly (ADP-ribosyl) transferase. The basic residues within the N-terminal region of this protein may bear potential DNA-binding properties, and may be involved in the nuclear and/or nucleolar targeting of the protein. Two alternatively spliced transcript variants encoding distinct isoforms have been found.
Description: The poly(ADP-ribose) polymerase family member 3 encoded by PARP3 belongs to the PARP family. These enzymes modify nuclear proteins by poly-ADP-ribosylation, which is required for DNA repair, regulation of apoptosis, and maintenance of genomic stability. This gene encodes the poly(ADP-ribosyl)transferase 3, which is preferentially localized to the daughter centriole throughout the cell cycle. Alternatively spliced transcript variants encoding different isoforms have been identified.
Description: The poly(ADP-ribose) polymerase family member 3 encoded by PARP3 belongs to the PARP family. These enzymes modify nuclear proteins by poly-ADP-ribosylation, which is required for DNA repair, regulation of apoptosis, and maintenance of genomic stability. This gene encodes the poly(ADP-ribosyl)transferase 3, which is preferentially localized to the daughter centriole throughout the cell cycle. Alternatively spliced transcript variants encoding different isoforms have been identified.
Description: The poly(ADP-ribose) polymerase family member 3 encoded by PARP3 belongs to the PARP family. These enzymes modify nuclear proteins by poly-ADP-ribosylation, which is required for DNA repair, regulation of apoptosis, and maintenance of genomic stability. This gene encodes the poly(ADP-ribosyl)transferase 3, which is preferentially localized to the daughter centriole throughout the cell cycle. Alternatively spliced transcript variants encoding different isoforms have been identified.
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human PARP . This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human PARP (Cleaved) . This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody for detection of PARP-1 Acetyl-K521) from Human, Mouse, Rat. This PARP-1 Acetyl-K521) antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human PARP-1 (Acetyl-K521) protein at amino acid sequence of K521
Description: A polyclonal antibody for detection of PARP-1 Acetyl-K521) from Human, Mouse, Rat. This PARP-1 Acetyl-K521) antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human PARP-1 (Acetyl-K521) protein at amino acid sequence of K521
Description: A polyclonal antibody for detection of PARP-1 Acetyl-K521) from Human, Mouse, Rat. This PARP-1 Acetyl-K521) antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human PARP-1 (Acetyl-K521) protein at amino acid sequence of K521
Description: This gene encodes a chromatin-associated enzyme, poly(ADP-ribosyl)transferase, which modifies various nuclear proteins by poly(ADP-ribosyl)ation. The modification is dependent on DNA and is involved in the regulation of various important cellular processes such as differentiation, proliferation, and tumor transformation and also in the regulation of the molecular events involved in the recovery of cell from DNA damage. In addition, this enzyme may be the site of mutation in Fanconi anemia, and may participate in the pathophysiology of type I diabetes.
Description: This gene encodes a chromatin-associated enzyme, poly(ADP-ribosyl)transferase, which modifies various nuclear proteins by poly(ADP-ribosyl)ation. The modification is dependent on DNA and is involved in the regulation of various important cellular processes such as differentiation, proliferation, and tumor transformation and also in the regulation of the molecular events involved in the recovery of cell from DNA damage. In addition, this enzyme may be the site of mutation in Fanconi anemia, and may participate in the pathophysiology of type I diabetes.
Description: This gene encodes a chromatin-associated enzyme, poly(ADP-ribosyl)transferase, which modifies various nuclear proteins by poly(ADP-ribosyl)ation. The modification is dependent on DNA and is involved in the regulation of various important cellular processes such as differentiation, proliferation, and tumor transformation and also in the regulation of the molecular events involved in the recovery of cell from DNA damage. In addition, this enzyme may be the site of mutation in Fanconi anemia, and may participate in the pathophysiology of type I diabetes.
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Cleaved PARP (Asp214) . This antibody is tested and proven to work in the following applications:
Description: A Rabbit Polyclonal antibody against PARP-1 (Acetyl-K521) from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, WB, ELISA
Description: A Rabbit Polyclonal antibody against PARP-1 (Acetyl-K521) from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, WB, ELISA
We analyzed the features of the spectrum of gene mutations and mutations signature pattern, and analyzed four pathways altered by mutations of genes in pancreatic neuroendocrine tumors, including DNA damage and repair, chromatin remodeling, maintenance of telomeres and activation of mTOR signaling.
